Molecular diagnostic test for rheumatoid arthritis under development by Tufts-New England Medical Center and the company.

Tufts-New England Medical Center (NEMC) and Source MDx will collaborate to develop a molecular diagnostic test for rheumatoid arthritis. Researchers at Tufts-NEMC, led by co-principal investigator, Tim McAlindon, M.D., chief of rheumatology at Tufts-NEMC, will manage the clinical studies for a molecular diagnostic test that will characterize rheumatoid arthritis patients and their response to anti-TNF therapy.

Source MDx will provide gene expression analysis of whole blood samples from the approximately 100 participating patient population based on its RA Precision Profile™ gene panel designed to diagnose and monitor RA patients and its Healthy Normals Reference dataset.

In conjunction with the Tufts-NEMC study, Source MDx was awarded an SBIR grant by the NIH to initiate the development of a molecular diagnostic test using biomarkers to predict responders and non responders to antitumor neurosis factor therapy for rheumatoid arthritis. The grant provides over $195,000 in funding over a one-year period.

Previous articleDirecting Genomic Evolution
Next articleZLB Behring to Buy MedImmune’s CytoGam®